Phase 1 N=24 Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment
Hepatic Impairment
Primary: Maximum Plasma Concentration (Cmax) of PF-05221304 — 1220; 1591; 1433; 1592 Nanogram per milliliter (ng/mL)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=30 Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis
Peritoneal Dialysis (PD) · Anemia · Chronic Kidney Disease
Primary: Pharmacokinetics (PK) of Triferic Iron Administered in Patients on Chronic Peritoneal Dialysis: Maximum Concentration (Cmax) of Serum Total Iron After Intraperitoneal…
Phase 1 N=72 A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Alogliptin and Pioglitazone — 165.3; 154.9; 162.3; 157.4 nanogram per milliliter (ng/ml) — p=0.014
Phase 1 N=26 Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
Central Nervous System Tumors
Primary: Measurement of Number of Adverse Events — 4; 6; 3; 5 Adverse events
Phase 1 N=12 Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects
Arthritis, Rheumatoid
Primary: Part 1: Change From Baseline Primary Soluble Inflammatory Mediators in Blood: Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL) 6 for LPS Arm — 2.4086; 0.2798…
Phase 1 N=26 Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
Relapsed and Refractory Multiple Myeloma
Primary: Number of Participants With One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 3; 3; 3; 3 Participants
Phase 1 N=63 Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma
Primary Open-angle Glaucoma (POAG) · Ocular Hypertension
Primary: Number of Participants With Treatment Emergent Adverse Event (TEAE) — 2; 0; 2; 0 Participants
Phase 1 N=52 Daprodustat Bioequivalence and Food Effect Study
Anaemia
Primary: Part 1:Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Last Measurable Concentration (AUC[0-t]) and AUC From Zero Hours Extrapolated to Infinity AUC…
Phase 1 N=50 Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis: A Pilot Feasibility Study
Shock, Septic
Primary: Compliance With Study Fluid Administration in the Assigned Study Arm — 0; 100 Proportion of total crystalloids adminis
Phase 1 N=120 Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD
Pulmonary Disease, Chronic Obstructive
Primary: Safety and Tolerability of BI 1026706, as Assessed by Frequency (in Percent) of Patients With Treatment Emergent Adverse Events (TEAEs) Over the Treatment Period…
Phase 1 N=376 Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
Non-small Cell Lung Cancer
Primary: Number of Participants Who Experienced Serious Adverse Events (SAE), Adverse Events (AE) Leading to Discontinuation, or Death — 4; 10; 8; 3 Participants
Phase 1 N=41 PK Study With Pantoprazole in Obese Children and Adolescents
Gastroesophageal Reflux Disease
Primary: Pharmacokinetic Analysis in Obese Children After One Single Oral Dose of Pantoprazole (Cmax). — 4.27; 4.1 mcg/ml
Phase 1 N=24 The Safety and Pharmacokinetics of Primapur and Gonal-f
Area Under Curve · Pharmacokinetics · Absorption
Primary: Area Under the Serum Concentration of Follicle Stimulating Hormone (FSH) - Time Curve (AUC(0-192)) — 1202.85; 1241.01 mIU*h/ml — p=0.05
Phase 1 N=24 The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)
Renal Insufficiency
Primary: [Parts 1 and 2] Mean Area Under the Concentration-Time Curve From Time Zero Up to Infinity (AUC0-inf) of Gefapixant 50 mg (Categorical Analysis) — 6450; 9970; 9990; 8590…
Phase 1 N=153 Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Renal Cell Carcinoma · Clear-cell Metastatic Renal Cell Carcinoma
Primary: Number of Participants With AEs, SAEs, and AEs Leading to Discontinuation — 3; 16; 13; 29 participants